Literature DB >> 27513154

Incidence of Neonatal Abstinence Syndrome - 28 States, 1999-2013.

Jean Y Ko, Stephen W Patrick, Van T Tong, Roshni Patel, Jennifer N Lind, Wanda D Barfield.   

Abstract

Neonatal abstinence syndrome (NAS) is a postnatal drug withdrawal syndrome that occurs primarily among opioid-exposed infants shortly after birth, often manifested by central nervous system irritability, autonomic overreactivity, and gastrointestinal tract dysfunction (1). During 2000-2012, the incidence of NAS in the United States significantly increased (2,3). Several recent publications have provided national estimates of NAS (2,3); however, data describing incidence at the state level are limited. CDC examined state trends in NAS incidence using all-payer, hospital inpatient delivery discharges compiled in the State Inpatient Databases of the Healthcare Cost and Utilization Project (HCUP) during 1999-2013. Among 28 states with publicly available data in HCUP during 1999-2013, the overall NAS incidence increased 300%, from 1.5 per 1,000 hospital births in 1999, to 6.0 per 1,000 hospital births in 2013. During the study period, significant increases in NAS incidence occurred in 25 of 27 states with at least 3 years of data, with annual incidence rate changes ranging from 0.05 (Hawaii) to 3.6 (Vermont) per 1,000 births. In 2013, NAS incidence ranged from 0.7 cases per 1,000 hospital births (Hawaii) to 33.4 cases per 1,000 hospital births (West Virginia). The findings underscore the importance of state-based public health programs to prevent unnecessary opioid use and to treat substance use disorders during pregnancy, as well as decrease the incidence of NAS.

Entities:  

Mesh:

Year:  2016        PMID: 27513154     DOI: 10.15585/mmwr.mm6531a2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  84 in total

1.  Positive Predictive Value of Administrative Data for Neonatal Abstinence Syndrome.

Authors:  Faouzi I Maalouf; William O Cooper; Shannon M Stratton; Judith A Dudley; Jean Ko; Anamika Banerji; Stephen W Patrick
Journal:  Pediatrics       Date:  2018-12-04       Impact factor: 7.124

2.  The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence Syndrome.

Authors:  Jason N Moore; Marc R Gastonguay; Chee M Ng; Susan C Adeniyi-Jones; David E Moody; Wenfang B Fang; Michelle E Ehrlich; Walter K Kraft
Journal:  Clin Pharmacol Ther       Date:  2018-04-28       Impact factor: 6.875

3.  Neurodevelopmental Outcomes of Neonates Randomized to Morphine or Methadone for Treatment of Neonatal Abstinence Syndrome.

Authors:  Adam J Czynski; Jonathan M Davis; Lynne M Dansereau; Barbara Engelhardt; Peter Marro; Debra L Bogen; Mark L Hudak; Jeffrey Shenberger; Elisha M Wachman; Erica L Oliveira; Barry M Lester
Journal:  J Pediatr       Date:  2020-01-24       Impact factor: 4.406

4.  Association of Rooming-in With Outcomes for Neonatal Abstinence Syndrome: A Systematic Review and Meta-analysis.

Authors:  Kathryn Dee L MacMillan; Cassandra P Rendon; Kanak Verma; Natalie Riblet; David B Washer; Alison Volpe Holmes
Journal:  JAMA Pediatr       Date:  2018-04-01       Impact factor: 16.193

5.  Goals and Objectives to Optimize the Value of an Acute Pain Service in Perioperative Pain Management.

Authors:  Linda Le-Wendling; Wesley Glick; Patrick Tighe
Journal:  Tech Orthop       Date:  2017-12

6.  Maternal buprenorphine treatment and fetal neurobehavioral development.

Authors:  Lauren M Jansson; Martha Velez; Krystle McConnell; Nancy Spencer; Michelle Tuten; Hendree E Jones; Van L King; Neeraj Gandotra; Lorraine A Milio; Kristin Voegtline; Janet A DiPietro
Journal:  Am J Obstet Gynecol       Date:  2017-02-07       Impact factor: 8.661

7.  US hospital discharges documenting patient opioid use disorder without opioid overdose or treatment services, 2011-2015.

Authors:  Cora Peterson; Likang Xu; Christina A Mikosz; Curtis Florence; Karin A Mack
Journal:  J Subst Abuse Treat       Date:  2018-06-20

8.  Maternal buprenorphine treatment and infant outcome.

Authors:  Lauren M Jansson; Martha L Velez; Krystle McConnell; Nancy Spencer; Michelle Tuten; Hendree Jones; Rebeca Rios; Van L King; Neeraj Gandotra; Lorraine Millio; Janet A DiPietro
Journal:  Drug Alcohol Depend       Date:  2017-08-31       Impact factor: 4.492

9.  Lactose-free infant formula does not change outcomes of neonatal abstinence syndrome (NAS): a randomized clinical trial.

Authors:  Rajesh Pandey; Neelakanta Kanike; Mugahid Ibrahim; Namita Swarup; Dennis M Super; Sharon Groh-Wargo; Deepak Kumar
Journal:  J Perinatol       Date:  2020-08-31       Impact factor: 2.521

10.  Capturing the statewide incidence of neonatal abstinence syndrome in real time: the West Virginia experience.

Authors:  Amna Umer; Sean Loudin; Stefan Maxwell; Christa Lilly; Meagan E Stabler; Lesley Cottrell; Candice Hamilton; Janine Breyel; Christina Mullins; Collin John
Journal:  Pediatr Res       Date:  2018-10-04       Impact factor: 3.756

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.